Mesa Laboratories MLAB Biopharmaceutical Development — Cost Of Goods And Services Sold Depreciation

Other segment segments

Similar metrics at other companies

LGNDDevelopment and Licensing of Biopharmaceutical Assets — Depreciation

$119K-76.8%

CWCOServices — Cost Of Goods And Services Sold Depreciation

$107.53K+18.7%

LHBiopharma Laboratory Services — Depreciation

$28.6M0.0%

TMOLaboratory Products and Biopharma Services — Depreciation of property, plant and equipment

$186M+8.1%

OPKPharmaceutical — Cost of Goods Sold

$22.3M-2.3%

THAll Other Segments — Cost Of Goods And Services Sold Depreciation

$868K-1.1%

Questions, answered.

What is Mesa Laboratories's biopharmaceutical development — cost of goods and services sold depreciation?

Mesa Laboratories (MLAB) reported biopharmaceutical development — cost of goods and services sold depreciation of $65K in Q1 2026.

How has Mesa Laboratories's biopharmaceutical development — cost of goods and services sold depreciation changed year-over-year?

Mesa Laboratories's biopharmaceutical development — cost of goods and services sold depreciation decreased by 13.3% year-over-year, from $75K to $65K.

What is the long-term trend for Mesa Laboratories's biopharmaceutical development — cost of goods and services sold depreciation?

Over 2 years (2024 to 2026), Mesa Laboratories's biopharmaceutical development — cost of goods and services sold depreciation has grown at a 17.3% compound annual growth rate (CAGR), from $224K to $308K.

What does biopharmaceutical development — cost of goods and services sold depreciation mean?

Captures the portion of depreciation expense allocated to the cost of goods sold for the Biopharmaceutical Development segment. This represents the systematic allocation of the cost of tangible assets used in the manufacturing or service delivery process. It is a key component in understanding the capital intensity of the segment's production operations.